Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 672

1.

Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team.

Pediatrics. 2007 Nov;120(5):e1190-202. Epub 2007 Oct 15.

PMID:
17938165
[PubMed - indexed for MEDLINE]
Free Article
2.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
[PubMed - indexed for MEDLINE]
3.

Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD.

Pediatrics. 2000 Jan;105(1):e11.

PMID:
10617748
[PubMed - indexed for MEDLINE]
4.

Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.

Richie E, Punjabi NH, Harjanto SJ, Wangsasaputral F, Sukandar M, Supriatman M, Simanjuntak CH, Que JU, Cryz SJ Jr.

Vaccine. 1999 Mar 17;17(11-12):1384-93.

PMID:
10195774
[PubMed - indexed for MEDLINE]
5.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
[PubMed - indexed for MEDLINE]
6.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.

Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.

Arch Pediatr Adolesc Med. 1994 May;148(5):503-7.

PMID:
8180641
[PubMed - indexed for MEDLINE]
7.

Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection.

Rosenblatt HM, Song LY, Nachman SA, Stanley KE, Krogstad PA, Johnson GM, Wiznia AA; Pediatric Aids Clinical Trials Group 377 Study Team.

J Allergy Clin Immunol. 2005 Sep;116(3):698-703.

PMID:
16159645
[PubMed - indexed for MEDLINE]
8.

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.

Vaccine. 2006 Jul 7;24(27-28):5627-36. Epub 2006 May 2.

PMID:
16740348
[PubMed - indexed for MEDLINE]
9.

One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.

Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.

Int J Infect Dis. 2007 Nov;11(6):488-95. Epub 2007 Mar 8.

PMID:
17349809
[PubMed - indexed for MEDLINE]
Free Article
10.

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, Borkowsky W, Rosenblatt HM, Marcinak JF, Dieudonne A, Abrams EJ, Pathak I; Pediatric AIDS Clinical Trials Group P1024 Protocol Team.

Pediatr Infect Dis J. 2006 Oct;25(10):920-9.

PMID:
17006288
[PubMed - indexed for MEDLINE]
11.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
[PubMed - indexed for MEDLINE]
12.

Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.

Bernstein HH, Rothstein EP, Pichichero ME, Francis AB, Kovel AJ, Disney FA, Green JL, Marsocci SM, Lynd AM, Wood GC, et al.

Am J Dis Child. 1992 May;146(5):556-9. Erratum in: Am J Dis Child 1992 Sep;146(9):1084. Am J Dis Child 1992 Jul;146(7):802.

PMID:
1621656
[PubMed - indexed for MEDLINE]
14.

Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Ciofi degli Atti ML, Mastrantonio P, Giammanco A; Progetto Pertosse Study Group.

Pediatrics. 2001 Feb;107(2):E25.

PMID:
11158499
[PubMed - indexed for MEDLINE]
15.

Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.

Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):282-94.

PMID:
19323013
[PubMed - indexed for MEDLINE]
16.

Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Warshaw M, Rosenblatt HM, Levin MJ, Nachman SA, Pelton SI, Borkowsky W, Fenton T; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams.

J Infect Dis. 2009 Sep 15;200(6):935-46. doi: 10.1086/605448.

PMID:
19663708
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.

Marcinak JF, Ward M, Frank AL, Boyer KM, Froeschle JE, Hosbach PH 4th.

Am J Dis Child. 1993 Mar;147(3):290-4. Erratum in: Am J Dis Child 1993 Jun;147(6):626.

PMID:
8438810
[PubMed - indexed for MEDLINE]
18.

Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.

Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.

Pediatr Infect Dis J. 2008 Apr;27(4):341-6. doi: 10.1097/INF.0b013e3181616180.

PMID:
18316985
[PubMed - indexed for MEDLINE]
19.

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.

Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C.

Scand J Infect Dis. 1996;28(2):159-63.

PMID:
8792483
[PubMed - indexed for MEDLINE]
20.

Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.

Tran Minh NN, He Q, Ramalho A, Kaufhold A, Viljanen MK, Arvilommi H, Mertsola J.

Pediatrics. 1999 Dec;104(6):e70.

PMID:
10586004
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk